Aditxt Acquires Appili Therapeutics
October 10, 2024
Aditxt, Inc. announced that Appili Therapeutics shareholders will vote on a proposed acquisition of all issued and outstanding shares of Appili through a plan of arrangement. Appili’s board recommended shareholders vote in favor, and Aditxt intends to use Appili’s infectious disease pipeline (including the FDA-approved LIKMEZ) to expand its reach in combating life-threatening infections and biodefense threats.
- Buyers
- Aditxt, Inc.
- Targets
- Appili Therapeutics Inc.
- Industry
- Healthcare Services
- Location
- Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Biogen Acquires Apellis Pharmaceuticals
March 31, 2026
Healthcare Services
Biogen entered into a definitive agreement to acquire Apellis Pharmaceuticals in a ~$5.6 billion cash deal ($41 per share) that also includes contingent value rights (CVRs) tied to SYFOVRE sales performance. The transaction closed in May 2026 and made Apellis a wholly owned subsidiary of Biogen, adding commercial products EMPAVELI and SYFOVRE to Biogen’s immunology/rare disease portfolio and strengthening its expansion into nephrology.
-
Aditxt Acquires Ignite Proteomics for $36 Million
March 19, 2026
Healthcare Services
Aditxt announced the $36 million acquisition of Ignite Proteomics, a commercial-stage precision oncology company. The deal was structured through the issuance of 36,000 shares of Aditxt’s newly designated Series A-2 convertible preferred stock, and Ignite will operate as a subsidiary within Aditxt’s oncology initiatives.
-
Aditxt, Inc. (via Adifem, Inc.) to Merge with Evofem Biosciences, Inc.
November 6, 2024
Healthcare Services
Evofem Biosciences announced it has secured voting agreements from certain Series E-1 stockholders and convertible noteholders to approve its proposed merger with Aditxt’s subsidiary, Adifem, Inc., under an amended and restated merger agreement. The deal would result in Evofem merging into and becoming a wholly owned subsidiary of Aditxt (with the surviving entity described as Evofem). Closing is subject to conditions including stockholder approval and Aditxt raising sufficient capital for approximately $17 million in cash payments (including funding a senior secured noteholder).
-
BiomX Acquires Adaptive Phage Therapeutics
March 18, 2024
Biotechnology
BiomX Inc. completed a stock-for-stock acquisition of Adaptive Phage Therapeutics (APT), making APT a wholly owned subsidiary and combining phage therapy capabilities and pipelines. Concurrently, BiomX raised $50 million in a private placement led by affiliates of Deerfield Management and the AMR Action Fund to advance two Phase 2 assets (BX004 and BX211) toward pivotal readouts in 2025–2026.
-
Aditxt Enters Revenue-Sharing Agreement with Cellvera in Connection with Proposed Acquisition of Cellvera
April 5, 2022
Biotechnology
Aditxt, Inc. has entered into a revenue-sharing agreement with Cellvera Global Holdings LLC and certain affiliates to support Aditxt’s proposed acquisition of Cellvera. The agreement provides Aditxt with up to 10% of net sales (up to $30 million) while enhancing the security for Cellvera’s loan to Aditxt and extending the due diligence period for the overall transaction.
-
Aditxt Signs Share Exchange Agreement to Acquire AiPharma Global Holdings
December 28, 2021
Healthcare Services
Aditxt (Nasdaq: ADTX) signed a share exchange agreement to acquire AiPharma Global Holdings LLC (AiPharma Global) in a two-step transaction involving an initial closing and a secondary closing, subject to conditions including regulatory, board, shareholder, and Nasdaq approvals. The deal would give Aditxt 9.5% of AiPharma at the initial closing and the remaining 90.5% at the secondary closing, with cash payments and Aditxt share issuance at each step.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.